Natsuko Yuge

Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM‐042 [(<i>E</i>)‐4‐(2‐(2‐(5,8‐dimethyl‐[1,2,4]triazolo[1,5‐<i>a</i>]pyrazin‐2‐yl)vinyl)‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)morpholine] in rats: potential for the treatment of schizophrenia

Keita Arakawa, Shunsuke Maehara, Natsuko Yuge et al. · Pharmacology Research & Perspectives · 2016 · 17 citations · Full text

Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats

Keita Arakawa, Natsuko Yuge, Shunsuke Maehara · Pharmacological Reports · 2020 · 10 citations